Strumento inattivo

Altre lingue Sarepta Therapeutics Inc Nasdaq

Azioni

US0023461041

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

17/05	SAREPTA THERAPEUTICS, INC. : prospettiva positiva di Mizuho Securities	ZM
14/05	SAREPTA THERAPEUTICS, INC. : Oppenheimer da Neutral a Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Sarepta Therapeutics : P.413-251 Seo et al. In situ biodistribution & localization of SRP-9003 in LGMD2ER4 Mice	10/05
Sarepta Therapeutics - Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	06/05
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health	03/05
Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says	02/05
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 EPS $0.73, vs. Street Est of $0.30	01/05
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q1 Revenue $413.5M, vs. Street Est of $370.5M	01/05
Sarepta Therapeutics Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Rise After Hours	01/05
Sarepta Therapeutics: Q1 Earnings Snapshot	01/05
Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments	01/05
Sarepta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results	24/04
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	04/04
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024	01/04
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29/03
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	21/03
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program	20/03
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	12/03
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	07/03
Sarepta Therapeutics to Present at Upcoming Investor Conferences	04/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Sarepta Therapeutics Inc Nasdaq

Azioni

US0023461041

Altre lingue

Filtri